Transient Nuclear Factor kappa B (NF-kappa B) Activation Stimulated by Interleukin-1beta May Be Partly Dependent on Proteasome Activity, but Not Phosphorylation and Ubiquitination of the Ikappa Balpha Molecule, in C6 Glioma Cells
REGULATION OF NF-kappa B LINKED TO CHEMOKINE PRODUCTION*

Takashi UeharaDagger , Junko MatsunoDagger , Masayuki KanekoDagger , Tadashi NishiyaDagger , Masahiro Fujimuro§, Hideyoshi Yokosawa§, and Yasuyuki NomuraDagger

From the Departments of Dagger  Pharmacology and § Biochemistry, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo 060-0812, Japan

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

We previously reported that several stresses can induce cytokine-induced neutrophil chemoattractant expression in a nuclear factor kappa B (NF-kappa B)-dependent manner. In this study, we focused further on the regulation of NF-kappa B. The activation of NF-kappa B and the subsequent cytokine-induced neutrophil chemoattractant induction in response to interleukin-1beta (IL-1beta ) were inhibited by proteasome inhibitors, MG132 and proteasome inhibitor I. Translocation of NF-kappa B into nuclei occurs by the phosphorylation, multi-ubiquitination, and degradation of Ikappa Balpha , a regulatory protein of NF-kappa B. Nascent Ikappa Balpha began to degrade 5 min after treatment with IL-1beta and disappeared completely after 15 min. However, Ikappa Balpha returned to basal levels after 45-60 min. Interestingly, resynthesized Ikappa Balpha was already phosphorylated at Ser-32. These results suggest that 1) the upstream signals are still activated, although the translocation of NF-kappa B peaks at 15 min; and 2) the regulated protein(s) acts downstream of Ikappa Balpha phosphorylation. Western blotting showed that the resynthesized and phosphorylated Ikappa B molecules were also upward-shifted by multi-ubiquitination in response to IL-1beta treatment. On the other hand, ATP-dependent Leu-Leu-Val-Tyr cleaving activity transiently increased, peaked at 15 min, and then decreased to basal levels at 60 min. Furthermore, the cytosolic fraction that was stimulated by IL-1beta for 15 min, but not for 0 and 60 min, could degrade phosphorylated and multi-ubiquitinated Ikappa Balpha . These results indicate that the transient translocation of NF-kappa B in response to IL-1beta may be partly dependent on transient proteasome activation.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Nuclear factor kappa B (NF-kappa B)1 participates in the regulation of the expression of multiple immediate-early genes involved in immune, acute-phase, and inflammatory responses (1). NF-kappa B is a heterodimer protein of the Rel family of transcription factors. In mammalian cells, the factors include p65 (RelA), RelB, c-Rel, p50/p105 (NF-kappa B1), and p52/p100 (NF-kappa B2). NF-kappa B proteins are constitutively present in cells and are retained in the cytoplasm associated with the inhibitory protein Ikappa B (2, 3). Activated NF-kappa B complexes, typically composed of p50 and p65, are translocated to the nucleus in response to several cytokines (TNF-alpha , IL-1beta , and IL-2), bacterial endotoxin, and stresses (UV, H2O2). (1, 4-6). The activation of NF-kappa B appears to require the phosphorylation and degradation of the Ikappa B proteins, thereby allowing the rapid translocation of NF-kappa B from the cytoplasm to the nucleus (4, 7-9). In particular, it has been shown that the phosphorylation of Ser-32 and Ser-36 and the ubiquitination at Lys-21 and Lys-22 are essential for targeting Ikappa B for signal-induced degradation by the ubiquitin/proteasome system (10).

The ubiquitin-dependent degradation of regulatory short-lived proteins plays an important role in cellular processes, including the cell cycle, immune system functions, inflammatory responses, and tissue differentiation. A key element in the regulation process is E3, a member of the ubiquitin-substrate ligase family of enzymes. After binding of the substrate through a specific structural motif, E3 transfers activated ubiquitin moieties from a ubiquitin-conjugating enzyme, E2, to a Lys residue in the target protein to generate a polyubiquitin chain. The tagged substrate is proteolyzed by a 26 S proteasome complex with the release of free and reutilizable ubiquitin (11-13). The activation of the enzymatic component of the ubiquitin system can render the substrates susceptible to conjugation and subsequent degradation. The proteasome is considered to be a crucial component in the ubiquitin-dependent proteolytic system (14). In this system, the proteasome functions in an ATP-dependent manner as a 26 S complex, which is assembled from a 20 S complex and other several regulatory subunits in the presence of ATP (15-17). These proteins are involved in physiological homeostasis processes such as the cell cycle, DNA replication, and stress response. However, regulation of these activities is unclear.

In this study, we attempted to elucidate how NF-kappa B activation in response to IL-1beta is regulated. We report that CINC production through NF-kappa B induced by IL-1beta is sensitive to proteasome inhibitors. The phosphorylation of Ser-32 and the degradation of Ikappa B occurred rapidly, followed by Ikappa Balpha protein resynthesis. Interestingly, we found that the resynthesized Ikappa Balpha protein was already phosphorylated (Ser-32), suggesting that upstream kinases are still activated during this period. Moreover, proteasome activity, but not ubiquitination, transiently increased during IL-1beta treatment accompanying NF-kappa B activation. We present here initial evidence that the chymotrypsin-like activity of the proteasome plays an important role in the cytokine-induced transient activation of NF-kappa B.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- C6 glioma cells were obtained from the American Type Culture Collection. Restriction endonucleases, dNTP mixture, and RNase inhibitor were purchased from Takara (Kyoto, Japan). Oligo(dT)12-18 primer, 5× first strand buffer, and reverse transcriptase were from Life Technologies, Inc. The Expand High Fidelity PCR system and rat IL-8 (CINC/gro) ELISA kits were obtained from Roche Molecular Biochemicals and Amersham International (Buckinghamshire, United Kingdom), respectively. Herbimycin A was obtained from Wako (Osaka, Japan). MG132 and PSI were purchased from Calbiochem. Anti-Ikappa Balpha and anti-phospho-specific Ikappa Balpha (Ser-32) antibodies were from Santa Cruz Biotechnology and New England Biolabs, Inc., respectively. Suc-Leu-Leu-Val-Tyr-4-methylcoumaryl-7-amide, benzyloxycarbonyl-leucyl-leucinal (calpain inhibitor), and E-64-d (inhibitor of thiol protease) were from Peptide Inc. (Osaka, Japan). All other reagents were purchased from Sigma.

Cell Culture-- C6 glioma cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, 50 µg/ml penicillin, and 100 µg/ml streptomycin in a humidified incubator containing 5% CO2.

RNA Isolation and PCR Analysis-- Total RNA was prepared from 1.2 × 107 cells using guanidium/cesium chloride as described previously (18, 19). PCR was performed on total RNA extracted from cultures. Total RNA (2 µg) was incubated at 37 °C for 60 min with a mixture of 100 units of reverse transcriptase, 1× first strand buffer, 10 mM DTT, a 0.5 mM concentration of each dNTP, and 50 units of RNase inhibitor to a final volume of 20 µl. The reaction mixture was then incubated for 10 min at 70 °C to inactive the reverse transcriptase. An aliquot (2 µl) of reverse transcriptase product was mixed with 1 milliunit of DNA polymerase and a 200 nM concentration of each of the sense and antisense primers in a buffer containing 1× PCR buffer and a 0.2 mM concentration of each dNTP in a final volume of 20 µl. The mixture was overlaid with 30 µl of liquid paraffin to prevent evaporation and then amplified by 20 cycles of PCR as described (19). The number of cycles that produced a linear relationship between the amount of input RNA and the resulting PCR products was used for each primer pair. The PCR products were resolved by electrophoresis on a 6% polyacrylamide gel in 0.5× Tris borate/EDTA. The gel was stained with ethidium bromide and photographed. The primers used are as follows: rat CINC-1, 5'-ATG GTC TCA GCC ACC CGC TCG-3' (positions 37-57; upstream) and 5'-GAC ACC CTT TAG CAT CTT TTG-3' (positions 298-318; downstream); rat Ikappa Balpha , 5'-TCT CCA CTC CGT CCT GCA GG-3' (positions 513-532; upstream) and 5'-TTA TAA CGT CAG ACG CTG GCC TCC-3' (positions 922-945; downstream); and rat GAPDH, 5'-AAA CCC ATC ACC ATC TTC CAG-3' (positions 238-258; upstream) and 5'-AGG GGC CAT CCA CAG TCT TCT-3' (positions 578-598; downstream).

ELISA-- ELISA for rat IL-8 (CINC/gro) antigen expressed in the culture supernatant was performed using a kit from Amersham International. The limit of detection was <0.08 ng/ml.

Electrophoretic Mobility Shift Assays (EMSAs)-- Nuclear extracts were prepared using previously described methods (6, 19). Briefly, 5 × 106 cells were harvested; washed once with 2 ml of ice-cold phosphate-buffered saline and resuspended in 400 µl of buffer containing 10 mM HEPES (pH 7.9), 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.5 mM phenylmethylsulfonyl fluoride, and 20 units/ml aprotinin. After incubation for 15 min on ice, Nonidet P-40 was added to a final concentration of 0.6%, and the mixture was vortexed vigorously for 10 s. The nuclei were precipitated; resuspended in 50 µl of buffer containing 20 mM HEPES (pH 7.9), 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1 mM phenylmethylsulfonyl fluoride, and 20 units/ml aprotinin; and vortexed vigorously for 15 min at 4 °C. The lysate were centrifuged at 15,000 rpm for 20 min at 4 °C, and the supernatants containing the nuclear proteins were transferred into new vials. The protein concentration of each extract was measured using a Bio-Rad protein assay kit.

EMSAs were performed by incubating 7.5 µg of nuclear extracts with 2 µg of poly(dI-dC) in binding buffer (10 mM Tris-HCl (pH 7.5), 50 mM NaCl, 1 mM EDTA, 1 mM DTT, 1 µg/ml bovine serum albumin, 0.05% Nonidet P-40, and 5% glycerol) in a 20-µl final volume for 30 min at 4 °C. Then, an end-labeled double-stranded oligonucleotide probe (50,000 cpm/0.3 ng) was added, and the reaction mixture was incubated for 15 min at room temperature. For the supershift assay with specific antibodies against NF-kappa B, nuclear extracts were preincubated with 1 µg of each antibody for 2 h at 4 °C before the addition of the end-labeled double-stranded oligonucleotide probe. Samples were separated by 5% native polyacrylamide gel electrophoresis in low ionic strength buffer (0.25× Tris borate/EDTA).

Oligonucleotides-- The double-stranded oligonucleotides used as competitors in the EMSA are as follows: blunt-ended competitors and NF-kappa B-binding site (5'-AGT TGA GGG GAC TTT CCC AGG C-3'; the core recognition sequence of this oligonucleotide is underlined).

Western Blot Analysis-- Cells (5 × 106) were washed twice with ice-cold phosphate-buffered saline, and then 200 µl of lysis buffer (10 mM HEPES (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM Na3VO4, 10 µg/ml aprotinin, 10 µg/ml leupeptin, 1 mM phenylmethylsulfonyl fluoride, 1 mM NaF, 1 mM DTT, and 1% Nonidet P-40) was added. In particular, for the detection of ubiquitinated Ikappa Balpha proteins, the cells were lysed with lysis buffer containing 0.1% SDS and 5 mM N-ethylmaleimide (20). The total lysates were centrifuged at 15,000 rpm for 30 min at 4 °C, and the supernatants were removed as crude cytosolic fractions. The cytosol was boiled with SDS sample buffer for 5 min. Equal amounts of each sample were subjected to 12% SDS-polyacrylamide gel electrophoresis at 100 V for 1 h at 4 °C, followed by transfer to a nitrocellulose filter. The filters were then blocked with 10 mM Tris-HCl (pH 7.5), 100 mM NaCl, and 0.1% Tween 20 containing 5% nonfat milk for 1 h at room temperature. Anti-Ikappa B and anti-phospho-specific Ikappa B antibodies were used as primary antibodies, and horseradish peroxidase-labeled rabbit Ig was used as the secondary antibody. The antibody-reactive bands were revealed by chemiluminescence (ECL Western detection kit).

Metabolic Labeling and Immunoprecipitation-- Cells (5 × 106) in 10-cm plates were washed twice with prewarmed (37 °C) methionine- and cysteine-free Dulbecco's modified Eagle's medium. The cells were then labeled 15 min before and 30 min after IL-1beta stimulation in 10 ml of methionine- and cysteine-free Dulbecco's modified Eagle's medium containing 0.2 mCi/ml Tran35S-label (ICN Biomedicals, Irvine, CA). Pulse-labeled cells were chased for various times for up to 60 and 240 min in complete medium containing 2.5 mM methionine and cysteine, respectively. At the end of each time point, the cells were solubilized on ice with lysis buffer. The lysates were immunoprecipitated using anti-Ikappa Balpha antibody and analyzed on 12% SDS-polyacrylamide gel. Dried gels on Whatman No. 3MM paper were exposed on an imaging plate and visualized on a Fuji BAS 2000 apparatus.

Assay for Chymotrypsin-like Activity in Cell Lysates-- Cells (1 × 106) were stimulated with 5 ng/ml IL-1beta for the indicated time periods (0-60 min) and then washed twice with ice-cold phosphate-buffered saline, scraped into 200 µl of lysis buffer (50 mM HEPES (pH 7.5), 2 mM ATP, 0.1 mM EDTA, 0.1 mM EGTA, and 1 mM DTT), and homogenized by 20 strokes in a Dounce homogenizer on ice. The homogenate was centrifuged at 10,000 × g for 10 min at 4 °C, and the resultant supernatants were centrifuged at 100,000 × g for 20 min or 5 h at 4 °C. Each supernatant was used for quantification of the chymotrypsin-like activity as described (21, 22). The activity was assayed at 37 °C for 15 min in 50 mM Tris-HCl (pH 7.8) containing 1 mM DTT, 2 mM ATP, 10 mM MgCl2, and 0.1 mM Suc-LLVY-4-methylcoumaryl-7-amide as a substrate. The reaction was stopped by adding 1 ml of 10% SDS. The amounts of released 4-methylcoumaryl-7-amide were measured with a spectrofluorometer (Hitachi F-2000 fluorescence spectrophotometer) with excitation at 380 nm and emission at 460 nm.

Ability to Degrade Ubiquitinated Ikappa Balpha in Cytosolic Fractions Stimulated by IL-1beta -- Cells (5 × 106) were stimulated with 5 ng/ml IL-1beta for the indicated time periods (0, 15, and 60 min), and the supernatants were isolated as described above and used for the assay of ubiquitinated Ikappa Balpha degradation. Each cytosolic fraction (20 µg) was incubated with the undegraded ubiquitinated Ikappa Balpha -accumulated fraction (40 µg) (see Fig. 7A, lane 6) at 37 °C for 60 min. The reaction was terminated by adding SDS sample buffer. The samples were then boiled for 5 min and subjected to 12% SDS-polyacrylamide gel electrophoresis, followed by transfer to a nitrocellulose filter. The degradation of ubiquitinated Ikappa Balpha was detected by Western blot analysis using anti-phospho-specific Ikappa B antibody.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Induction of CINC mRNA and Protein in Response to IL-1beta -- Initially, we examined whether mRNA levels of CINC and GAPDH were affected by IL-1beta . A 24-h exposure to IL-1beta did not alter cell viability (data not shown). Furthermore, the housekeeping gene GAPDH mRNA was not altered at the stages examined (Fig. 1A). CINC mRNA was not detected after treatment with IL-1beta . Kinetic analysis showed that IL-1beta -induced CINC mRNA expression peaked at 30-60 min. We then used ELISA to investigate the levels of CINC protein after treatment with IL-1beta . Treatment resulted in time-dependent induction of CINC proteins into the culture supernatant. CINC proteins were significantly elevated 12 h after IL-1beta challenge and continued to accumulate for up to 48 h (Fig. 1B).


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 1.   Induction of CINC mRNA and protein in response to IL-1beta in C6 glioma cells. The mRNA levels were analyzed by RT-PCR using CINC-specific primers as described under "Experimental Procedures." The number of cycles selected for each primer pair produced a linear relationship between the amounts of input RNA and the PCR products. The PCR products were electrophoresed on 6% polyacrylamide gels and visualized by ethidium bromide staining. These are typical results from four independent experiments. CINC protein in the culture medium was detected by a specific ELISA. The data represent the results of four independent experiments. Each value is the mean ± S.E. (error bars) of four determinations. A, time course of CINC mRNA induction by 5 ng/ml IL-1beta ; B, IL-1beta -induced release of CINC protein. open circle , control; , 5 ng/ml IL-1beta .

Inhibitory Effects of Proteasome Inhibitors and Herbimycin A on IL-1beta -induced CINC mRNA and Protein Expression-- To elucidate the involvement of proteasomes and herbimycin A-sensitive proteins (possibly tyrosine kinases) in IL-1beta -induced CINC expression, we investigated the effects of several inhibitors. Both MG132 and PSI, which are cell-permeable protease inhibitors, attenuated CINC mRNA induction in a concentration-dependent manner (Fig. 2, A and B). Furthermore, CINC proteins were significantly suppressed by pretreatment with either inhibitor (Fig. 2D). Herbimycin A, a potent tyrosine kinase inhibitor, also attenuated CINC mRNA and protein expression (Fig. 2, C and D).


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 2.   Effects of protease inhibitors and herbimycin A on IL-1beta -stimulated CINC expression. Cells were pretreated with the indicated concentrations of MG132, PSI, and herbimycin A (Herb A) for 1, 2, and 12 h, respectively, and then stimulated with 5 ng/ml IL-1beta for 30 min (for RT-PCR assay) or 6 h (for ELISA). Total cellular RNA and the culture medium were prepared and analyzed by RT-PCR and ELISA in as described in the legend of Fig. 1. Values represent the mean ± S.E. of triplicate cultures run in parallel. **, p < 0.01 versus effect of IL-1beta alone.

Induction and Identification of NF-kappa B Complexes in Response to IL-1beta -- We previously demonstrated that NF-kappa B activation in C6 glioma cells in response to several stresses is involved in CINC expression (19). In this study, we examined whether IL-1beta can also induce NF-kappa B activation. Nuclear extracts were prepared, and samples were subjected to EMSA using a DNA probe containing the NF-kappa B-binding element as described under "Experimental Procedures." As shown in Fig. 3A, no binding of NF-kappa B to radiolabeled probes was detected in unstimulated cells. However, after treatment with IL-1beta , there was significant transient binding, peaking at 15 min. Binding completely disappeared when the nuclear extracts were incubated with non-radiolabeled DNA (Fig. 3B). Supershift assays in EMSA using specific antibodies against NF-kappa B p50 and p65 revealed that IL-1beta -stimulated NF-kappa B is a heterodimer (p50/p65) (Fig. 3C).


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 3.   IL-1beta activates NF-kappa B binding activity. The cells were treated with 5 ng/ml IL-1beta for the time periods indicated, and nuclear extracts were prepared and subjected to EMSA as described under "Experimental Procedures." For supershift assays, nuclear extracts were incubated in the presence of 1 µg of specific antibodies against each NF-kappa B component and an excess of unlabeled DNA probe (5-50-fold with the probe). CT represents control rabbit IgG. A, time course of NF-kappa B activation induced by IL-1beta ; B, competition analysis of NF-kappa B; C, identification of the NF-kappa B component.

Since proteasome inhibitors and herbimycin A suppressed IL-1beta -induced CINC mRNA and protein expression, we examined the effects of these inhibitors on NF-kappa B activation by IL-1beta . Proteasome inhibitors and herbimycin A partially and completely attenuated NF-kappa B activation, respectively (Fig. 4).


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 4.   Effects of protease inhibitors and herbimycin A on IL-1beta -stimulated NF-kappa B activation. Cells were pretreated with 10 µM MG132, 20 µM PSI, or 1 µg/ml herbimycin A (Herb A) for 1, 2, or 12 h, respectively, and then stimulated with 5 ng/ml IL-1beta for 15 min. Nuclear extracts were prepared and subjected to EMSA as described under "Experimental Procedures."

Ikappa Balpha Is Degraded and Thereafter Rapidly Resynthesized during IL-1beta Treatment-- NF-kappa B activation is mainly dependent on Ikappa B degradation. Before degradation, Ikappa B is serine-phosphorylated by Ikappa B kinase and then ubiquitinated by ubiquitin ligase (23). We analyzed Ikappa Balpha levels at the indicated sampling times by Western blotting using anti-Ikappa Balpha antibody. The levels of Ikappa Balpha were decreased after 5 min in response to IL-1beta and then disappeared after 15 min. Surprisingly, Ikappa Balpha was re-detected at 30 min and returned to basal levels at 45-60 min (Fig. 5A). Cycloheximide, a protein synthesis inhibitor, completely blocked the resynthesis of Ikappa Balpha . Proteasome inhibitors and herbimycin A, which inhibited NF-kappa B activation by IL-1beta , blocked the degradation of Ikappa Balpha . Fig. 5B shows the mRNA levels of Ikappa Balpha during IL-1beta treatment. Ikappa Balpha mRNA was detected 5 min after stimulation and peaked at 45-60 min.


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 5.   Resynthesis and phosphorylation of Ikappa Balpha at Ser-32 in C6 glioma cells challenged with IL-1beta . Cells were pretreated with 10 µM MG132, 20 µM PSI, 1 µg/ml herbimycin A (Herb A), or 0.1 µM cycloheximide (CHX) for 1, 2, 12, or 1 h, respectively, and then stimulated with 5 ng/ml IL-1beta for the indicated time periods. Cytosolic extracts (20 µg) and total RNA from the cells were subjected to Western blot analysis and RT-PCR, respectively. A, detection of Ikappa Balpha during IL-1beta treatment by Western blot analysis using anti-Ikappa Balpha antibody; B, detection of resynthesized Ikappa Balpha mRNA by the RT-PCR method; C, detection of the phosphorylated state of Ikappa Balpha by Western blot analysis using anti-phospho-specific (Ser-32) Ikappa Balpha antibody. Total cell extracts from HeLa cells prepared with TNF-alpha (10 ng/ml, 5 min) treatment were used as positive controls (P. C.).

The phosphorylation of Ikappa Balpha at Ser-32 and Ser-36 stimulates conjugation with ubiquitin and subsequent proteasome-mediated degradation, resulting in the translocation of NF-kappa B. Therefore, the phosphorylation of Ikappa Balpha at Ser-32 and Ser-36 is essential for the activation of NF-kappa B. We investigated whether Ikappa Balpha is phosphorylated in response to IL-1beta using antibody that specifically recognizes the phosphorylated Ser-32 on Ikappa Balpha . No detectable bands were observed in the unstimulated state. Treatment with IL-1beta stimulated the phosphorylation of Ikappa Balpha at 5 min, and then all phosphorylated Ikappa Balpha was degraded at 15 min. Interestingly, resynthesized Ikappa Balpha was phosphorylated at Ser-32 (Fig. 5C). Although neither MG132 nor PSI influenced the phosphorylation of Ikappa Balpha , herbimycin A completely inhibited IL-1beta -induced serine phosphorylation.

Next, we performed a pulse-chase study to examine the degradation rates during IL-1beta stimulation in C6 glioma cells. The cells were labeled 15 min before and 30 min after IL-1beta stimulation in medium containing [35S]Met/Cys and chased in medium containing 2.5 mM Met and Cys for 60 and 240 min, respectively. As shown in Fig. 6A, nascent Ikappa Balpha degraded rapidly and almost disappeared 15 min after IL-1beta stimulation, with a time course similar to the results of Western blot analysis using anti-Ikappa Balpha antibody (Fig. 5A). Thereafter, Ikappa Balpha protein was not detected. However, as shown in Fig. 6B, the resynthesized Ikappa Balpha protein was not degraded, as seen in the early step (0-15 min after stimulation). These results indicate that the degradation rates of Ikappa Balpha in the early (0-15 min after stimulation) and late (45-240 min) steps are different.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 6.   Degradation state of Ikappa Balpha during IL-1beta treatment. Cells were metabolically labeled for 15 min with Tran35S-label during the time periods indicated by the closed bars and then chased for the indicated time periods. In B, the cells were stimulated by IL-1beta for 30 min and then metabolically labeled for 15 min with exposure to a similar concentration of IL-1beta . Thereafter, the cells were chased for up to 240 min. The reaction was stopped at each time indicated by the arrows. Ikappa Balpha proteins were immunoprecipitated and analyzed on SDS-polyacrylamide gels as described under "Experimental Procedures."

IL-1beta Transiently Enhances Chymotrypsin-like Activity, but Not Ubiquitination-- We further examined how the activation of NF-kappa B is regulated. It is believed that the phosphorylation and multi-ubiquitination of Ikappa B are critical for degradation by 26 S proteasomes. We first measured the multi-ubiquitination state of Ikappa Balpha by Western blotting using anti-phospho-specific Ikappa Balpha antibody because only phosphorylated Ikappa B molecules are ubiquitinated. We prepared cell extracts at different times after treatment of C6 cells with 5 ng/ml IL-1beta in the presence or absence of MG132 and then analyzed the samples by Western blotting. The extracts were prepared in the presence of SDS (0.1%) and N-ethylmaleimide (5 mM) to inhibit isopeptidase activities, as described (20). As shown in Fig. 7A, a ladder of high molecular mass proteins appeared following stimulation with IL-1beta . The molecular mass increments of this ladder were ~8.5 kDa, which is the size of ubiquitin. The ubiquitination of Ikappa Balpha peaked at 5 min following stimulation and then decreased at 15 min. Resynthesized and phosphorylated Ikappa Balpha was upward-shifted again by 30-60 min. We next examined the effect of MG132 on IL-1beta -induced ladder formation. Treatment of C6 cells with MG132 alone (60 min) led to a slight accumulation of phosphorylated and ubiquitinated Ikappa Balpha . Although MG132 inhibited the degradation of Ikappa Balpha , but not its phosphorylation (Fig. 5C), phosphorylated and ubiquitinated Ikappa Balpha proteins were clearly detected under these conditions (Fig. 7B). The ubiquitination of Ikappa Balpha peaked at 15 min after stimulation and then decreased by 30-60 min, possibly because of residual activities of proteasomes and isopeptidases.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 7.   Multi-ubiquitination of Ikappa Balpha and activation of proteasomes in response to IL-1beta . Cells were pretreated with (B) or without (A) 10 µM MG132 for 1 h and then stimulated with 5 ng/ml IL-1beta for the indicated time periods. The cell extraction buffer contained 0.1% SDS and 5 mM N-ethylmaleimide. The extracts (40 µg) were then subjected to Western blot analysis using anti-phospho-specific (Ser-32) Ikappa Balpha antibody. The time course of proteasome activities stimulated by IL-1beta is shown (C). Cells were stimulated with 5 ng/ml IL-1beta for the indicated time periods (0-60 min) and washed twice with ice-cold phosphate-buffered saline. The cytosolic fraction was prepared as described under "Experimental Procedures." The activity toward Suc-LLVY-4-methylcoumaryl-7-amide was assayed in the presence of 2 mM ATP. p-Ikappa Balpha , phosphorylated Ikappa Balpha ; [Ub]n-p-Ikappa Balpha , multi-ubiquinated p-Ikappa Balpha .

On the other hand, chymotrypsin-like (Suc-LLVYase) activity in the presence of ATP in the proteasome-containing fraction, which was prepared by centrifugation at 100,000 × g for 20 min, was transiently enhanced and peaked 15 min after IL-1beta stimulation (Fig. 7C). In contrast, the activity in the cytosolic fraction prepared by centrifugation at 100,000 × g for 5 h was reduced to ~75% of the sample prepared by centrifugation at 100,000 × g for 20 min because the high molecular mass proteasomes (700-1000 kDa) are precipitated by the prolonged centrifugation.2 In addition, we measured the activity in the TNF-alpha -treated cytosolic fractions. TNF-alpha , which can induce NF-kappa B activation, also increased Suc-LLVYase activity in a similar manner to IL-1beta -treated cells.3 Next, we investigated the effects of several inhibitors on IL-1beta -enhanced proteasome activation. The cells were pretreated with MG132 or PSI for a specified time period; the cytosolic fractions were isolated; and the activity was measured. The proteasome inhibitors (MG132 and PSI) completely blocked the activity in a quiescent state, and enhancement of the activity was induced by IL-1beta (data not shown). Treatment with E-64-d, a thiol proteinase inhibitor, did not affect the activation in response to IL-1beta . In addition, herbimycin A (a potent tyrosine kinase inhibitor), benzyloxycarbonyl-leucyl-leucinal (a calpain inhibitor), and Ro 31-8220 (a nonspecific serine/threonine kinase inhibitor) did not alter enhancement by IL-1beta .

To elucidate the causality between the enhancement of Suc-LLVYase activity and the degradation of phosphorylated and multi-ubiquitinated Ikappa Balpha , we finally analyzed the ability to degrade ubiquitinated Ikappa Balpha in IL-1beta -stimulated cytosolic fractions. As shown in Fig. 8, only the cytosol stimulated by IL-1beta for 15 min, but not for 0 or 60 min, could degrade ubiquitinated Ikappa Balpha in the cytosol 60 min after IL-1beta stimulation. Treatment with 10 µM MG132 suppressed the degradation of Ikappa Balpha (Fig. 8, lane 4).


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 8.   Degradation of ubiquitinated Ikappa Balpha in IL-1beta -stimulated cytosolic fractions. Cells were stimulated with 5 ng/ml IL-1beta for 60 min, and then the cytosolic fraction containing undegraded ubiquitinated Ikappa Balpha was prepared as described under "Experimental Procedures." The proteasome-containing cytosolic fractions were prepared from the cells stimulated with 5 ng/ml IL-1beta for the indicated time periods (0, 15, and 60 min). Each cytosolic fraction was incubated with the undegraded ubiquitinated Ikappa Balpha -accumulated fraction at 37 °C for 60 min. The reaction was terminated by adding SDS sample buffer. The degradation of ubiquitinated Ikappa Balpha was detected by Western blot analysis using anti-phospho-specific Ikappa B antibody. p-Ikappa Balpha , phosphorylated Ikappa Balpha ; [Ub]n-p-Ikappa Balpha , multi-ubiquitinated p-Ikappa Balpha .


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The aim of this study was to investigate the mechanism of NF-kappa B regulation, especially via Ikappa Balpha , in C6 glioma cells. We showed here that IL-1beta stimulates NF-kappa B activation and subsequent chemokine (CINC) production. Activation was sensitive to proteasome inhibitors (MG132 and PSI) and herbimycin A, indicating that both the proteasome, which degrades Ikappa Balpha , and a tyrosine kinase are involved in this pathway. Furthermore, IL-1beta treatment resulted in the rapid resynthesis of Ikappa Balpha . Surprisingly, we found that Ser-32 in resynthesized Ikappa Balpha was already phosphorylated. Although the phosphorylation of this residue is important for ubiquitination and degradation, no significant translocation of NF-kappa B was observed. These results suggest that some proteins downstream from the serine phosphorylation of Ikappa Balpha inhibit degradation signaling. Therefore, we further examined why the activation of NF-kappa B stimulated by IL-1beta is transient.

Recent studies have provided some insights into the mechanisms leading to Ikappa Balpha degradation (7, 20, 24-30). The signal-induced degradation of Ikappa Balpha is dependent on the presence of an intact COOH-terminal PEST (Pro, Glu, Ser, Thr) region as well as the phosphorylation of Ser-32 and Ser-36. These phosphorylated residues probably target the molecule for ubiquitination at Lys-21 and Lys-22 (29, 30). In turn, this targets the molecule for degradation by 26 S proteasomes (20), which occurs when the inhibitor and NF-kappa B are dissociated. The Ikappa Balpha molecule is resynthesized rapidly following degradation, partly because the promoter of the Ikappa Balpha gene is positively regulated by NF-kappa B. We confirmed that IL-1beta stimulates the phosphorylation and degradation of Ikappa B and its de novo resynthesis (Fig. 5).

Surprisingly, we found that resynthesized Ikappa Balpha is already phosphorylated at Ser-32, indicating that the receptor-mediated signal for phosphorylation is active in IL-1beta -challenged C6 glioma cells for at least up to 60 min. Why does phosphorylated Ikappa Balpha not cause further NF-kappa B translocation? To address this problem, we examined the activities of ubiquitin ligase and proteasomes. We first measured the state of ubiquitination of the Ikappa Balpha molecule by Western blotting. The multi-ubiquitination of Ikappa Balpha was detected by anti-phospho-specific Ikappa Balpha antibody. Multi-ubiquitinated Ikappa Balpha proteins were detected as upward-shifted proteins (20). Treatment with IL-1beta stimulated ubiquitination (Fig. 7A). However, multi-ubiquitinated proteins disappeared 15 min after IL-1beta challenge, and resynthesized Ikappa Balpha was phosphorylated and ubiquitinated. In addition, pretreatment with MG132, a proteasome inhibitor, caused the accumulation of multi-ubiquitinated Ikappa Balpha , which peaked 15 min after IL-1beta treatment. These results suggest that multi-ubiquitination in response to IL-1beta is present for at least up to 60 min after treatment. In addition, phosphorylated and resynthesized Ikappa Balpha proteins and the accumulated phosphorylated Ikappa Balpha protein in MG132-pretreated cytosolic fractions were barely dephosphorylated (Fig. 5C). These results suggest that inactivated enzyme such as some phosphatases is not mainly involved, or the activity has a very low level in this system, although the modification of Ikappa Balpha (serine phosphorylation) that is essential for NF-kappa B activation rapidly occurs.

We next examined Suc-LLVY cleaving activity in the cytosolic fraction. The chymotrypsin-like (Suc-LLVYase) activity in the proteasome-containing cytosolic fraction prepared by centrifugation at 100,000 × g for 20 min in response to IL-1beta was transiently activated with a time course similar to that of NF-kappa B translocation (Fig. 7C). Since it is well known that LLVY is a substrate for chymotrypsin (which is slight in glial cells), calpain, and 20 S and 26 S proteasomes, the activity in the cytosolic fraction may be derived from these proteins. We first investigated the possibility that the chymotrypsin-like (LLVYase) activity is partly derived from proteasome activity. The activity in the cytosolic fraction prepared by centrifugation at 100,000 × g for 5 h was reduced markedly compared with that in the sample prepared by centrifugation at 100,000 × g for 20 min because the high molecular mass proteasomes (700-1000 kDa) are precipitated by prolonged centrifugation. The resulting activity is considered to be derived from another protein such as calpain, and there was no enhancement of the activity seen during IL-1beta treatment. Moreover, the calpain inhibitor did not block IL-1beta -stimulated Ikappa B degradation in this system, suggesting that at least the proteasome is partly activated by treatment with IL-1beta . These results indicate that a transient increase in Suc-LLVY cleaving activity is partly derived from the proteasome activity. However, the time courses of Suc-LLVYase and NF-kappa B translocation are merely coincidental; we cannot completely rule out the possibility that the other proteinase is involved in Suc-LLVY cleavage and Ikappa B degradation.

Subsequently, we studied the mechanism of the transient Suc-LLVYase activation stimulated by IL-1beta using several inhibitors: E-64-d (a thiol protease inhibitor), Ro 31-8220 (a nonspecific serine/threonine kinase inhibitor), and herbimycin A (a potent tyrosine kinase inhibitor). Pretreatment with these inhibitors did not affect IL-1beta -stimulated Suc-LLVYase activation. There have been few reports on the transient activation of proteasomes in response to several cytokines that can stimulate NF-kappa B translocation. However, Kawahara et al. (21) reported that the 26 S proteasome is activated in prophase and metaphase during the mitotic cell cycle of synchronously dividing ascidium embryos. Furthermore, proteasomes are activated during in vivo Xenopus egg activation induced by treatment with the calcium ionophore A23187 (22). The 26 S proteasome consists of at least two subunits: one is a 700-kDa proteolytic core complex called the 20 S proteasome with 28 subunits, and the other is a 700-1000-kDa regulatory subunit complex made up of ~20 subunits (31-38). Although there are many reports that several proteasome subunits can be phosphorylated, there is little or no direct effect on proteasome activity from these modifications (39-42). Thus, it is believed that phosphorylation is involved in assembly, targeting, or turnover of proteasome subunits. In contrast, Kenneth et al. (43) demonstrated that the phosphorylation of PA28, referred to as the 11 S regulator, is required for stimulation of peptidase activity, although the relevant mechanism remains to be defined. Therefore, in our system, it may be possible that some modifications such as phosphorylation are involved in the modulation of Suc-LLVYase activity, possibly 26 S proteasome activity; however, we could not directly demonstrate how the 26 S proteasome is regulated.

It is recognized that the level of resynthesized Ikappa Balpha proteins is very important for the down-regulation of NF-kappa B activity. We have found here that the resynthesized proteins are phosphorylated and multi-ubiquitinated. If the proteasome is involved in the degradation of Ikappa Balpha as reported previously, it was clearly expected that resynthesized (phosphorylated and ubiquitinated) Ikappa Balpha would also be degraded, and then the activation of NF-kappa B would occur again. However, these events did not occur. Alternatively, if ubiquitinated Ikappa Balpha is degraded by other proteinase in this system, the rates of degradation in the early (0-15 min after stimulation) and late (45-240 min after stimulation) steps could be the same. However, pulse-chase analysis showed that the rates are quite different (Fig. 6). We suspect that the enzyme(s) involved in the degradation of Ikappa Balpha are down-regulated in the late stage (45-240 min after IL-1beta stimulation). Hence, we investigated the ability to degrade ubiquitinated Ikappa Balpha in each cytosolic fraction (0, 15, and 60 min after IL-1beta stimulation). As shown in Fig. 8, only the cytosol stimulated by IL-1beta for 15 min, but not for 0 or 60 min, could degrade the accumulated ubiquitinated Ikappa Balpha protein in the cytosol 60 min after stimulation. This reaction was suppressed by proteasome inhibitor treatment. Therefore, these findings indicate that the down-regulation of proteasome activity is partly involved in the NF-kappa B system. However, we cannot completely deny the possibility that the transient increase in proteasome activity is a secondary effect of IL-1beta stimulation, although the two processes (proteasome activation and NF-kappa B activation) are merely coincidental. As indicated above, another alternative is that other proteinases may be implicated in this process. For example, it has been reported that calpain, another possible regulator of the Ikappa B/NF-kappa B system, can degrade Ikappa B. Chen et al. (44) reported that calpain contributes to Ikappa Balpha degradation stimulated by silica, but not by lipopolysaccharide. However, Traenckner et al. (28) reported that calpain is not primarily involved in TNF-alpha -induced Ikappa Balpha degradation. Therefore, we investigated whether or not calpain is involved in Ikappa Balpha degradation using a calpain inhibitor. The m-calpain inhibitor benzyloxycarbonyl-leucyl-leucinal was not effective, suggesting that calpain is not primarily involved in this system.

We demonstrated here that both NF-kappa B activation and CINC expression in response to IL-1beta are completely inhibited by treatment with herbimycin A in C6 glioma cells. Since herbimycin A also blocked phosphorylation of Ikappa Balpha at Ser-32 by IL-1beta , an intermediate protein between the receptor and Ikappa B kinase may exist. However, a herbimycin A-sensitive protein involved in IL-1beta -stimulated signaling has not been found. We have previously reported that NF-kappa B activation is essential for inducible nitric-oxide synthase and CINC expression in response to lipopolysaccharide, TNF-alpha , and H2O2 in a herbimycin A-dependent manner (6, 19). Taken together, our results suggest that there is a common pathway mediating the stress-stimulated signaling through a herbimycin A-sensitive protein (possibly tyrosine kinase).

We propose here a novel regulation system for NF-kappa B activation. In glial cells, IL-1beta induces the rapidly sequential phosphorylation, ubiquitination, and degradation of Ikappa Balpha and the subsequent NF-kappa B translocation into the nuclei that peaks 15 min after IL-1beta treatment. Receptor-mediated signals seem to be activated at least 60 min after stimulation. We demonstrated that the transient enhancement of Suc-LLVYase (possibly proteasome) activity has a time course similar to that of the translocation of NF-kappa B. It is obvious that the regulation of proteasome activity partly contributes to the transient NF-kappa B activation. Furthermore, the cytosolic fraction stimulated by IL-1beta for 15 min, but not for 0 and 60 min, had an ability to degrade ubiquitinated Ikappa Balpha . In view of these results, it is suggested that the transient increase in proteasome activity is partly involved in the NF-kappa B regulation. Therefore, delineating the precise mechanisms of proteasome activation in response to IL-1beta is needed.

    FOOTNOTES

* This work was supported by a grant-in-aid for scientific research from the Ministry of Education, Science, Sports, and Culture of Japan.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed. Tel.: 81-11-706-3246; Fax: 81-11-706-4987; E-mail: nomura{at}pharm.hokudai.ac.jp.

2 T. Uehara, M. Kaneko, and Y. Nomura, unpublished data.

3 T. Uehara and Y. Nomura, unpublished data.

    ABBREVIATIONS

The abbreviations used are: NF-kappa B, nuclear factor kappa B; TNF-alpha , tumor necrosis factor alpha ; IL, interleukin; E2, ubiquitin carrier protein; E3, ubiquitin-protein isopeptide ligase; CINC, cytokine-induced neutrophil chemoattractant; PCR, polymerase chain reaction; ELISA, enzyme-linked immunosorbent assay; PSI, proteasome inhibitor I; Suc-, succinyl-; DTT, dithiothreitol; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; EMSA, electrophoretic mobility shift assay; LLVY, Leu-Leu-Val-Tyr; RT, reverse transcription.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
  1. Baeuerle, P. A., and Henkel, T. (1994) Annu. Rev. Immunol. 12, 141-179[CrossRef][Medline] [Order article via Infotrieve]
  2. Beg, A. A., and Baldwin, A. S., Jr. (1993) Genes Dev. 7, 2064-2070[CrossRef][Medline] [Order article via Infotrieve]
  3. Gilmore, T. D., and Morin, P. J. (1993) Trends Genet. 9, 427-433[CrossRef][Medline] [Order article via Infotrieve]
  4. Henkel, T., Machleidt, T., Alkalay, I., Kronke, M., Ben-Neriah, Y., and Baeuerle, P. A. (1993) Nature 365, 182-185[CrossRef][Medline] [Order article via Infotrieve]
  5. Donald, R., Ballard, D. W., and Hawiger, J. (1995) J. Biol. Chem. 270, 9-12[Abstract/Free Full Text]
  6. Nishiya, T., Uehara, T., and Nomura, Y. (1995) FEBS Lett. 371, 333-336[CrossRef][Medline] [Order article via Infotrieve]
  7. Alkalay, I., Yaron, A., Hatzubai, A., Jung, S., Avraham, A., Gerlitz, O., Pashut-Lavon, I., and Ben-Neriah, Y. (1995) Mol. Cell. Biol. 15, 1294-1299[Abstract]
  8. DiDonato, J. A., Mercurio, F., and Karin, M (1995) Mol. Cell. Biol. 15, 1302-1311[Abstract]
  9. Thanos, D., and Maniatis, T. (1995) Cell 80, 573-582[Medline] [Order article via Infotrieve]
  10. Baldwin, A. S., Jr. (1996) Annu. Rev. Immunol. 14, 649-651[CrossRef][Medline] [Order article via Infotrieve]
  11. Jentsch, S., and Schlenker, S. (1995) Cell 82, 881-884[Medline] [Order article via Infotrieve]
  12. Ciechanover, A. (1994) Cell 79, 13-21[Medline] [Order article via Infotrieve]
  13. Ciechanover, A. (1996) Nat. Med. 2, 1188-1191[Medline] [Order article via Infotrieve]
  14. Matthews, W., Driscoll, J., Tanaka, K., Ichihara, A., and Goldberg, A. L. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 2597-2601[Abstract]
  15. Eytan, E., Ganoth, D., Armon, T., and Hershko, A. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 7751-7755[Abstract]
  16. Driscoll, J., and Goldberg, A. L. (1990) J. Biol. Chem. 265, 4789-4792[Abstract/Free Full Text]
  17. Orino, E., Tanaka, K., Tamura, T., Sone, S., Ogura, T., and Ichihara, A. (1991) FEBS Lett. 284, 206-210[CrossRef][Medline] [Order article via Infotrieve]
  18. Uehara, T., Kikuchi, Y., and Nomura, Y. (1999) J. Neurochem. 72, 196-205[CrossRef][Medline] [Order article via Infotrieve]
  19. Uehara, T., Baba, I., and Nomura, Y. (1998) Brain Res. 790, 284-292[CrossRef][Medline] [Order article via Infotrieve]
  20. Chen, Z., Hagler, J., Palombella, V. J., Melandri, F., Scherer, D., Ballard, D., and Maniatis, T. (1995) Genes Dev. 9, 1586-1597[Abstract]
  21. Kawahara, H., Sawada, H., and Yokosawa, H. (1992) FEBS Lett. 310, 119-122[CrossRef][Medline] [Order article via Infotrieve]
  22. Aizawa, H., Kawahara, H., Tanaka, K., and Yokosawa, H. (1996) Biochem. Biophys. Res. Commun. 218, 224-228[CrossRef][Medline] [Order article via Infotrieve]
  23. DiDonato, J. A., Hayakawa, M., Rothwarf, D. M., Zandi, E., and Karin, M. (1997) Nature 388, 548-554[CrossRef][Medline] [Order article via Infotrieve]
  24. Brown, K., Gerstberger, S., Carlson, L., Franzoso, G., and Siebenlist, U. (1995) Science 267, 1485-1491[Medline] [Order article via Infotrieve]
  25. Rodriguez, M. S., Michalopoulos, I., Arenzana-Seisdedos, F., and Hay, R. T. (1995) Mol. Cell. Biol. 15, 2413-2419[Abstract]
  26. Brockman, J. A., Scherer, D. C., Hall, S. M., McKinsey, T. A., Qi, X., Lee, W. Y., and Ballard, D. W. (1995) Mol. Cell. Biol. 15, 2809-2818[Abstract]
  27. Whiteside, S. T., Ernst, M. K., LeBail, O., Laurent-Winter, C., Rice, N., and Israel, A. (1995) Mol. Cell. Biol. 15, 5339-5345[Abstract]
  28. Traenckner, E. B.-M., Pahl, H. L., Henkel, T., Schmidt, K. N., Wilk, S., and Baeuerle, P. A. (1995) EMBO J. 14, 2876-2883[Abstract]
  29. Scherer, D. C., Brockman, J. A., Chen, Z., Maniatis, T., and Ballard, D. W. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 11259-11263[Abstract]
  30. Baldi, L., Brown, K., Franzoso, G., and Siebenlist, U. (1996) J. Biol. Chem. 271, 376-379[Abstract/Free Full Text]
  31. Goldberg, A. L. (1992) Eur. J. Biochem. 203, 9-23[Medline] [Order article via Infotrieve]
  32. Hershko, A., and Ciechanover, A. (1992) Annu. Rev. Biochem. 61, 761-807[CrossRef][Medline] [Order article via Infotrieve]
  33. Hoffman, L., Pratt, G., and Rechsteiner, M. (1992) J. Biol. Chem. 267, 22362-22368[Abstract/Free Full Text]
  34. Sawada, H., Muto, K., Fujimuro, M., Akaishi, T., Takagi Sawada, M., Yokosawa, H., and Goldberg, A. L. (1993) FEBS Lett. 335, 207-212[CrossRef][Medline] [Order article via Infotrieve]
  35. Udvardy, A. (1993) J. Biol. Chem. 268, 9055-9062[Abstract/Free Full Text]
  36. Chu-Ping, M., Vu, J. H., Proske, R. J., Slaughter, C. A., and DeMartino, G. N. (1994) J. Biol. Chem. 269, 3539-3547[Abstract/Free Full Text]
  37. Peters, J.-M., Franke, W. W., and Kleinschmidt, J. A. (1994) J. Biol. Chem. 269, 7709-7718[Abstract/Free Full Text]
  38. Yoshimura, T., Kameyama, K., Takagi, T., Ikai, A., Tokunaga, F., Koide, T., Tanahashi, N., Tamura, T., Cejka, Z., Baumeister, W., Tanaka, K., and Ichihara, A. (1993) J. Struct. Biol. 111, 200-211[CrossRef][Medline] [Order article via Infotrieve]
  39. Weitman, D., and Etlinger, J. D. (1992) J. Biol. Chem. 267, 6977-6982[Abstract/Free Full Text]
  40. Ludemann, R., Lerea, K. M., and Etlinger, J. D. (1993) J. Biol. Chem. 268, 17413-17417[Abstract/Free Full Text]
  41. Etlinger, J. D., Li, S. X., Guo, G. G., and Li, N. (1993) Enzyme Protein 47, 325-329[Medline] [Order article via Infotrieve]
  42. Castano, J. G., Mahillo, E., Arizti, P., and Arribas, J. (1996) Biochemistry 35, 3782-3789[CrossRef][Medline] [Order article via Infotrieve]
  43. Kenneth, N. L., Lerea, M., and Etlinger, J. D. (1996) Biochem. Biophys. Res. Commun. 225, 855-860[CrossRef][Medline] [Order article via Infotrieve]
  44. Chen, F., Lu, Y., Kuhn, D. C., Maki, M., Shi, X., Sun, S.-C., and Demers, L. M. (1997) Arch. Biochem. Biophys. 342, 383-388[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.